The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Open accessAbstract
OBJECTIVES. To systematically review the literature on inborn errors of metabolism, neonatal screening technology and screening programmes in order to analyse the costs and benefits of introducing screening based on tandem mass-spectrometry (tandem MS) for a wide range of disorders of amino acid and organic acid metabolism in the UK. To evaluate screening for cystic fibrosis, Duchenne muscular dystrophy and other disorders which are tested on an individual basis. HOW THE RESEARCH WAS CONDUCTED. Systematic searches were carried out of the literature on inborn errors of metabolism, neonatal screening programmes, tandem MS-based neonatal screening technology, economic evaluations of neonatal screening programmes and psychological aspects of neonatal screening. Background material on the biology of inherited metabolic disease, the basic philosophy, and the history and current status of the UK screening programme was also collected. Relevant papers in the grey literature and recent publications were identified by hand-searching. Each paper was graded. For each disease an aggregate grade for the state of knowledge in six key areas was awarded. Additional data were prospectively collected on activity and costs in UK neonatal screening laboratories, and expert clinical opinion on current treatment modalities and outcomes. These data were used to construct a decision-analysis model of neonatal screening technologies, comparing tandem MS with the existing phenylketonuria screening methods. This model determined the cost per additional case identified and, for each disease, the additional treatment costs per case, and the cost per life-year saved. All costs and benefits were discounted at 6% per annum. One-way sensitivity analysis was performed showing the effect of varying the discount rate, the incidence rate of each disorder, the number of neonates screened and the cost of tandem MS, on the cost per life-year gained. RESEARCH FINDINGS. The UK screening programmes for phenylketonuria and congenital hypothyroidism have largely achieved the expected objectives and are cost-effective. Current concerns are the difficulty of maintaining adequate coverage, perceived organisational weaknesses, and a lack of overview. For many of the organic acid disorders it was necessary to rely on data obtained from clinically-diagnosed cases. Many of these diseases can be treated very effectively and a sensitive screening test was available for most of the diseases. Except for cystic fibrosis, there have been no randomised controlled trials of the overall effectiveness of neonatal screening. Despite the anxiety generated by the screening process, there is strong parental support for screening. The effects of diagnosis through screening on subsequent reproductive behaviour is less clear. Conflicts exist between current concepts and the traditional principles of screening. The availability of effective treatment is not an absolute prerequisite: early diagnosis is of value to the family concerned and, to the extent that is leads to increased use of prenatal diagnosis, may help to reduce the overall burden of disease. Neonatal screening is also of value in diseases which present early but with non-specific symptoms. Indeed, almost all of the diseases considered could merit neonatal screening. The majority of economic evaluations failed to incorporate the health benefits from screening, and therefore failed to address the value of the information which the screening programmes provided to parents. The marginal cost of changing from present technology to tandem MS would be approximately 0.60 pounds per baby at a workload of 100,000 samples a year, and 0.87 pounds at 50,000 samples per year. The ability to screen for a wider range of diseases would lead to the identification of some 20 additional cases per 100,000 infants screened, giving a laboratory cost per additional diagnosis of 3000 pounds at an annual workload of 100,000 babies per year.(ABSTRACT TRUNCATED)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–222 of 222
Ranieri, E., Ryall, R., Morris, C. P., et al. (1992) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(92)90081-s · Cited by 19
Congenital Hypothyroidism: Physiological and Psychological Factors in Early Development
Murphy, G. H., Hulse, J. A., Smith, I., & Grant, D. (1990) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.1990.tb00812.x · Cited by 19
Organ transplantation for inherited metabolic disease.
Kelly, D. A. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.71.3.181 · Cited by 19
Liver transplantation in tyrosinaemia type 1: the dilemma of timing the operation
Salt, A., Barnes, N. D., Rolles, K., Calne, R., Clayton, P. T., & Leonard, J. V. (1992) · Acta Paediatrica · doi:10.1111/j.1651-2227.1992.tb12270.x · Cited by 18
Neonatal screen for hereditary tyrosinaemia type I
HOLME, E. (1992) · The Lancet · doi:10.1016/0140-6736(92)92724-t · Cited by 17
Sensory neuropathy and vitamin B6 treatment in homocystinuria
Ludolph, A. C., Masur, H., Oberwittler, C., Koch, H. G., & Ullrich, K. (1993) · European Journal of Pediatrics · doi:10.1007/bf01956164 · Cited by 17
Neonatal Screening: Life‐Stress Scores in Families Given a False‐Positive Result
FYRÖ, K. (1988) · Acta Paediatrica · doi:10.1111/j.1651-2227.1988.tb10635.x · Cited by 17
Liver transplantation in tyrosinaemia type I: the Groningen experience
Wijburg, F. A., Reitsma, W. C. C., Slooff, M. J. H., van Spronsen, F. J., Koetse, H. A., Reijngoud, D., Smit, G., Berger, R., & Bijleveld, C. M. A. (1995) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00711743 · Cited by 16
The costs and benefits of screening for congenital hypothyroidism in Wisconsin
Barden, H. S., & Kessel, R. (1984) · Biodemography and Social Biology · doi:10.1080/19485565.1984.9988574 · Cited by 16
Smith, I., & Brenton, D. P. (1995) · Springer eBooks · doi:10.1007/978-3-662-03147-6_12 · Cited by 16
Flye, M. W., Riely, C. A., Hainline, B. E., Sassa, S., Gusberg, R. J., Blakemore, K. J., Barwick, K. W., & Horwich, A. L. (1990) · Transplantation · doi:10.1097/00007890-199005000-00017 · Cited by 15
Congenital hypothyroidism missed on screening.
Grant, G. A., Carson, D. J., Reid, M. M., & Hutchinson, J. M. (1986) · Archives of Disease in Childhood · doi:10.1136/adc.61.2.189 · Cited by 13
Attitudes of Parents of Cystic Fibrosis Children Towards Neonatal Screening and Antenatal Diagnosis
Al-Jader, L. N., GOODCHILD, M. C., Ryley, H. C., & Harper, P. S. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5934-0_32 · Cited by 13
A Neonatal Screening Test for Argininosuccinic Acid Lyase Deficiency and Other Urea Cycle Disorders
Talbot, H. W., Sumlin, A. B., Naylor, E. W., & Guthrie, R. W. (1982) · PEDIATRICS · doi:10.1542/peds.70.4.526 · Cited by 12
Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation.
Noble-Jamieson, G., Jamieson, N., Clayton, P. T., Bailey, S., Ryalls, M. R., & Barnes, N. D. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.70.6.544 · Cited by 12
Clinical aspects of congenital adrenal hyperplasia: Early diagnosis and prognosis
Hughes, I. A. (1986) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01800865 · Cited by 10
Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.
Green, M. R., Weaver, L. T., & Heeley, A. F. (1994) · Archives of Disease in Childhood · doi:10.1136/adc.70.3.252 · Cited by 8
Elevated 17‐Hydroxyprogesterone Levels in Premature Infants
Knudtron, J., Markestad, T., Aakvaag, A., & Bergjø, P. (1991) · Acta Paediatrica · doi:10.1111/j.1651-2227.1991.tb11737.x · Cited by 6
Newborn Screening Metabolic Disorders
Mamunes, P. (1976) · Clinics in Perinatology · doi:10.1016/s0095-5108(18)31283-1 · Cited by 6
Cystic fibrosis in teenagers and young adults.
Conway, R. P. (1996) · Archives of Disease in Childhood · doi:10.1136/adc.75.2.99 · Cited by 5
Audit of screening for congenital hypothyroidism.
Singh, A., & Logan, S. (1993) · Archives of Disease in Childhood · doi:10.1136/adc.68.3.432-d · Cited by 4
Role of the Clinical Biochemistry Laboratory in the Management of Very Low Birthweight infants
Henderson, M. J., & Dear, P. R. (1993) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329303000402 · Cited by 2
Cited by
Shevell, M., Ashwal, S., Donley, D., Flint, J., Gingold, M., Hirtz, D., Majnemer, A., Noetzel, M., & Sheth, R. D. (2003) · Neurology · doi:10.1212/01.wnl.0000031431.81555.16 · Cited by 829
Development and validation of methods for assessing the quality of diagnostic accuracy studies
Whiting, P., Rutjes, A., Dinnes, J., Reitsma, J., Bossuyt, P., & Kleijnen, J. (2004) · Health Technology Assessment · doi:10.3310/hta8250 · Cited by 372
Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review
Green, J., Hewison, J., Bekker, H., Bryant, L., & Cuckle, H. (2004) · Health Technology Assessment · doi:10.3310/hta8330 · Cited by 368
Chace, D. H., Kalas, T. A., & Naylor, E. W. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.022502.103213 · Cited by 210
How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia?
Grosse, S. D., & Van Vliet, G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000098400 · Cited by 102
Metadata
- Authors
- Pollitt, Green, McCabe, Booth, Cooper, Leonard, Nicholl, Nicholson, Tunaley, & Virdi
- Venue
- Health Technology Assessment
- Published
- 1997
- Volume
- 1
- Issue
- 7
- Pages
- i-iv, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2137680310
- Cited by
- 267
- References
- 222
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.